Akari Therapeutics Enters Share Purchase Agreement with White Lion Capital, CFO Resigns

Akari Therapeutics has entered a share purchase agreement with White Lion Capital, allowing it to sell up to $25 million in newly issued Ordinary Shares. The company's CFO, Torsten Hombeck, has announced his resignation effective October 10, 2025. Analysts rate AKTX stock as a Buy with a $5.00 price target. The stock has a neutral technical analysis trend, but its speculative nature and lack of revenue highlight significant challenges.

Akari Therapeutics (AKTX), a biopharmaceutical company focused on developing treatments for rare and orphan diseases, has entered into a significant share purchase agreement with White Lion Capital. This agreement, effective August 29, 2025, allows Akari to sell up to $25 million in newly issued Ordinary Shares. The transaction provides Akari with flexibility in terms of timing and amount, contingent upon market conditions and regulatory approvals [1].

The company's Chief Financial Officer (CFO), Torsten Hombeck, has announced his resignation effective October 10, 2025. However, he will remain as a consultant until at least November 30, 2025, to ensure a smooth transition. This change in leadership comes as the company continues to navigate its financial instability and lack of revenue [1].

Analysts have rated AKTX stock as a Buy with a $5.00 price target, reflecting a positive outlook despite the company's current challenges. The most recent analyst rating indicates a neutral trend in the technical analysis, but the speculative nature of the stock due to the absence of traditional valuation metrics underscores the significant risks involved [1].

Akari's pipeline includes several promising drug candidates, such as investigational nomacopan, a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The company is also conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA) and a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) [2].

The stock's average trading volume is 32,836, and its current market cap is $26.32 million. Despite the recent corporate events, the technical sentiment signal for AKTX remains Sell, indicating a cautious approach among investors [1].

Additionally, the company's CEO, Gaslightwala Abizer, has recently acquired 21,000 American Depositary Shares, representing Ordinary Shares, in three separate transactions. The total purchase amount was $19,540, with weighted average prices per share ranging from $0.90 to $0.94 [3].

In conclusion, while the share purchase agreement with White Lion Capital provides Akari with much-needed flexibility, the company faces significant challenges, including financial instability and a lack of revenue. The resignation of the CFO and the stock's speculative nature highlight the risks involved. However, the company's pipeline of drug candidates and recent corporate events may offer some potential for strategic improvement.

References:
[1] https://www.tipranks.com/news/company-announcements/akari-therapeutics-enters-share-purchase-agreement
[2] https://www.marketscreener.com/news/akari-therapeutics-plc-enters-ordinary-share-purchase-agreement-with-white-lion-capital-ce7c50dddc80f120
[3] https://www.tradingview.com/news/tradingview:b3a46ffc73237:0-akari-therapeutics-ceo-acquires-21-000-shares/